Rani Therapeutics Holdings(RANI)
$0.56+0.02 (+3.52%)
RANI
Rani Therapeutics Holdings financials statements
$0.56
At close:+0.02 (+3.52%)
Want to see RANI full AI Analyst Report?
Rani Therapeutics Holdings (RANI) Ratios
1,593 Followers
Rani Therapeutics Holdings Ratios
RANI's free cash flow for Q3 2026 was $-7.94M. For the 2026 fiscal year, RANI's free cash flow was decreased by $-183.00K and operating cash flow was $-7.76M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.21 | 1.50 | 6.36 | 20.96 | 45.30 |
| Quick Ratio | 4.21 | 1.50 | 6.36 | 20.96 | 45.30 |
| Cash Ratio | 1.47 | 0.19 | 0.73 | 5.61 | 44.49 |
| Solvency Ratio | -1.68 | -0.87 | -1.02 | -0.88 | -2.97 |
| Operating Cash Flow Ratio | -1.48 | -1.78 | -6.41 | -9.66 | -12.21 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -2.37 | -10.46 | 0.00 | 0.00 |
| Net Current Asset Value | $ 36.21M | $ -3.40M | $ 18.37M | $ 66.90M | $ 116.95M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.81 | 0.52 | 0.28 | 0.00 |
| Debt-to-Equity Ratio | 0.13 | 14.91 | 2.34 | 0.82 | 0.00 |
| Debt-to-Capital Ratio | 0.12 | 0.94 | 0.70 | 0.45 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.08 | 0.83 | 0.66 | 0.44 | 0.00 |
| Financial Leverage Ratio | 1.78 | 18.39 | 4.50 | 2.93 | 2.62 |
| Debt Service Coverage Ratio | -12.85 | -3.85 | -6.54 | -57.63 | -111.86 |
| Interest Coverage Ratio | -13.25 | -10.59 | -13.00 | -59.24 | -110.73 |
| Debt to Market Cap | 0.03 | 0.63 | 0.35 | 0.21 | 0.00 |
| Interest Debt Per Share | 0.11 | 1.22 | 1.38 | 1.31 | 0.02 |
| Net Debt to EBITDA | 0.38 | -0.51 | -0.37 | -0.05 | 2.26 |
| Profitability Margins | |||||
| Gross Profit Margin | 44.89% | 100.00% | 0.00% | 0.00% | 100.00% |
| EBIT Margin | -2330.62% | -5014.69% | 0.00% | 0.00% | -1935.26% |
| EBITDA Margin | -2275.51% | -4914.69% | 0.00% | 0.00% | -1916.97% |
| Operating Profit Margin | -2345.99% | -5186.19% | 0.00% | 0.00% | -1899.12% |
| Pretax Profit Margin | -2507.65% | -2920.04% | 0.00% | 0.00% | -1952.41% |
| Net Profit Margin | -1817.09% | -2920.04% | 0.00% | 0.00% | -306.62% |
| Continuous Operations Profit Margin | -2507.65% | -5504.28% | 0.00% | 0.00% | -1953.92% |
| Net Income Per EBT | 72.46% | 100.00% | 50.04% | 48.34% | 15.70% |
| EBT Per EBIT | 106.89% | 56.30% | 102.70% | 99.72% | 102.81% |
| Return on Assets (ROA) | -50.62% | -81.94% | -58.65% | -28.32% | -6.71% |
| Return on Equity (ROE) | -89.89% | -1506.93% | -264.03% | -83.00% | -17.57% |
| Return on Capital Employed (ROCE) | -83.37% | -318.43% | -132.39% | -61.48% | -42.44% |
| Return on Invested Capital (ROIC) | -80.59% | -160.57% | -119.01% | -60.88% | -42.44% |
| Return on Tangible Assets | -50.62% | -81.94% | -58.65% | -28.32% | -6.71% |
| Earnings Yield | -33.23% | -76.95% | -40.12% | -21.77% | -2.61% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.80 | 2.40 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 2.91 | 0.00 | 1.27 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.32 | 0.15 | 0.00 | 0.00 | 0.59 |
| Asset Turnover | 0.03 | 0.03 | 0.00 | 0.00 | 0.02 |
| Working Capital Turnover Ratio | 0.06 | 0.04 | 0.00 | 0.00 | 0.03 |
| Cash Conversion Cycle | 331.10 | 151.96 | -287.74 | 0.00 | 0.00 |
| Days of Sales Outstanding | 456.42 | 151.96 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 125.32 | 0.00 | 287.74 | 0.00 | 0.00 |
| Operating Cycle | 456.42 | 151.96 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.28 | -1.25 | -2.01 | -1.95 | -1.65 |
| Free Cash Flow Per Share | -0.28 | -1.26 | -2.06 | -2.02 | -1.68 |
| Dividend Paid and CapEx Coverage Ratio | -212.66 | -132.45 | -41.69 | -28.73 | -63.73 |
| Capital Expenditure Coverage Ratio | -212.66 | -132.45 | -41.69 | -28.73 | -63.73 |
| Operating Cash Flow Coverage Ratio | -4.33 | -1.19 | -1.70 | -1.54 | 0.00 |
| Operating Cash Flow to Sales Ratio | -11.46 | -34.53 | 0.00 | 0.00 | -11.87 |
| Free Cash Flow Yield | -21.06% | -91.67% | -61.96% | -34.25% | -10.25% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.00 | -1.30 | -2.49 | -4.59 | -38.34 |
| Price-to-Sales (P/S) Ratio | 54.68 | 37.95 | 0.00 | 0.00 | 117.55 |
| Price-to-Book (P/B) Ratio | 2.70 | 19.58 | 6.58 | 3.81 | 6.74 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.75 | -1.09 | -1.61 | -2.92 | -9.75 |
| Price-to-Operating Cash Flow Ratio | -4.77 | -1.10 | -1.65 | -3.02 | -9.90 |
| Price-to-Earnings Growth (PEG) Ratio | 0.05 | 0.06 | -0.64 | -0.02 | 0.76 |
| Enterprise Value Multiple | -2.02 | -1.29 | -1.67 | -2.33 | -3.88 |
| Enterprise Value | 74.99M | 64.96M | 108.91M | 143.73M | 201.93M |
| EV to EBITDA | -2.02 | -1.29 | -1.67 | -2.33 | -3.88 |
| EV to Sales | 45.92 | 63.19 | 0.00 | 0.00 | 74.32 |
| EV to Free Cash Flow | -3.99 | -1.82 | -2.08 | -2.99 | -6.17 |
| EV to Operating Cash Flow | -4.01 | -1.83 | -2.13 | -3.09 | -6.26 |
| Tangible Book Value Per Share | 0.63 | 0.12 | 1.00 | 3.11 | 6.22 |
| Shareholders’ Equity Per Share | 0.50 | 0.07 | 0.50 | 1.55 | 2.43 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.89 | 0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.02 | 0.04 | 0.00 | 0.00 | 0.14 |
| Net Income Per Share | -0.45 | -1.05 | -1.33 | -1.28 | -0.43 |
| Tax Burden | 0.72 | 1.00 | 0.50 | 0.48 | 0.16 |
| Interest Burden | 1.08 | 0.58 | 1.03 | 1.02 | 1.01 |
| Research & Development to Revenue | 12.37 | 25.96 | 0.00 | 0.00 | 9.75 |
| SG&A to Revenue | 12.09 | 23.29 | 0.00 | 0.00 | 10.24 |
| Stock-Based Compensation to Revenue | 7.22 | 15.59 | 0.00 | 0.00 | 8.32 |
| Income Quality | 0.63 | 0.63 | 1.51 | 0.73 | 3.87 |
Currency in USD

